Mitapivat

• CAT Number: I001039
• CAS Number: 1260075-17-9
• Molecular Formula: C24H26N4O3S
• Molecular Weight: 450.55
• Purity: ≥95%
• Target: PKR
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: N-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide
• InChI: InChI=1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2
• InChIKey: XAYGBKHKBBXDAK-UHFFFAOYSA-N
• SMILES: C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5

Mitapivat (CAT: I001039) is a small molecule allosteric activator of the pyruvate kinase-R (PKR) enzyme, which plays a key role in glycolysis. By activating PKR, mitapivat promotes the conversion of phosphoenolpyruvate (PEP) to pyruvate, leading to increased ATP production. This mechanism of action makes mitapivat a potential therapeutic agent for inherited red blood cells disorders, such as pyruvate kinase deficiency (PKD) and sickle cell disease (SCD). In clinical trials, mitapivat has shown promising results in improving red blood cell parameters, reducing hemolysis, and increasing hemoglobin levels in patients with PKD and SCD. It represents a novel approach to the treatment of these hematological disorders.

Reference

[1]. PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY. Patent WO/2012/151451A1